Goldman Sachs
CRSP icon

Goldman Sachs’s CRISPR Therapeutics CRSP Stock Holding History

Goldman Sachs’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,300
Closed -$1.51M – 6495
2025
Q3 		$1.51M Hold
23,300
– – ﹤0.01% 4719
2025
Q2 		$1.13M Buy
+23,300
New +$902K ﹤0.01% 4602
2022
Q1 		– Sell
-80,000
Closed -$6.06M – 6611
2021
Q4 		$6.06M Buy
+80,000
New +$6.99M ﹤0.01% 3223
2020
Q1 		– Sell
-23,300
Closed -$1.42M – 5247
2019
Q4 		$1.42M Buy
+23,300
New +$1.27M ﹤0.01% 3892

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's CRSP Position: Q1 2026 in Review

Goldman Sachs increased its CRISPR Therapeutics (CRSP) stake by 50% in Q1 2026, buying an estimated $7.31M and bringing the position to 414,220 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Goldman Sachs first reported a position in CRSP in Q4 2017 and has held it in 34 quarters since. The position peaked at $48.7M in Q3 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Goldman Sachs held 414,220 shares of CRISPR Therapeutics worth $19.7M as of Q1 2026.
  • Goldman Sachs bought 138,588 CRISPR Therapeutics shares in Q1 2026, an estimated $7.31M.
  • CRISPR Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2448 holding.
  • Goldman Sachs first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • Goldman Sachs's CRISPR Therapeutics position peaked at $48.7M in Q3 2022.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.